nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.06.2017 | Review Article

Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment

verfasst von: Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard, Robert S. Kirsner

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic disorder with prototypical clinical presentations. Its pathophysiology is complex and not fully explained. Recent information regarding the genetic basis of PG and the role of auto-inflammation provides a better understanding of the disease and new therapeutic targets. PG equally affects patients of both sexes and of any age. Uncontrolled cutaneous neutrophilic inflammation is the cornerstone in a genetically predisposed individual. Multimodality management is often required to reduce inflammation, optimize wound healing, and treat underlying disease. A gold standard for the management of PG does not exist and high-level evidence is limited. Multiple factors must be taken into account when deciding on the optimum treatment for individual patients: location, number and size of lesion/ulceration(s), extracutaneous involvement, presence of associated disease, cost, and side effects of treatment, as well as patient comorbidities and preferences. Refractory and rapidly progressive cases require early initiation of systemic therapy. Newer targeted therapies represent a promising pathway for the management of PG, and the main focus of this review is the management and evidence supporting the role of new targeted therapies in PG.

Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211.PubMedCrossRef

Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.PubMedPubMedCentralCrossRef

Hafner J, Nobbe S, Partsch H, Lauchli S, Mayer D, Amann-Vesti B, et al. Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol. 2010;146(9):961–8.PubMedCrossRef

Weizman A, Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cutan Med Surg. 2015;19:125–31.PubMed

Shahid S, Myszor M, De Silva A. Pyoderma gangrenosum as a first presentation of inflammatory bowel disease. BMJ Case Rep. 2014;2014:pii:bcr2014204853.

Ahronowitz I, Harp J, Shinkai K. Etiology and mangement of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13:191–211.PubMedCrossRef

Gameiro A, Pereira N, Cardoso JC, Goncalo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:285–93.PubMedPubMedCentralCrossRef

Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF 3rd, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Investig Dermatol. 1998;111:259–68.PubMedCrossRef

Magro CM, Kiani B, Li J, Crowson AN. Clonality in the setting of Sweet’s syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease. J Cutan Pathol. 2007;34(7):526–34.PubMedCrossRef

10.

Jabbari H, Payvarmehr F, SeyedAlinaghi S, Roosta N. A case report of cyclic neutropenia associated with pyoderma gangrenosum. Acta Med Iran. 2011;49(11):763–5.PubMed

11.

Mehta AJ, Charman CR. Pyoderma gangrenosum in association with autoimmune neutropenia of infancy. Pediatr Dermatol. 2008;25(6):620–2.PubMedCrossRef

12.

Thakur N, Sodani R, Chandra J, Singh V. Leukocyte adhesion defect type 1 presenting with recurrent pyoderma gnagrenosum. Indian J Dermatol. 2013;58:158.PubMedPubMedCentralCrossRef

13.

Butler D, Shinkai K. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary. Dermatol Clin. 2013;31(3):427–35.PubMedCrossRef

14.

Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–8.PubMedCrossRef

15.

Steele RB, Nugent WH, Braswell SF, Frisch S, Ferrell J, Ortega-Loayza AG. Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment. Br J Dermatol. 2016;174(1):77–87.PubMedCrossRef

16.

Palanivel JA, Macbeth AE, Levell NJ. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation. Clin Exp Dermatol. 2013;38(1):44–6.PubMedCrossRef

17.

Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149(6):762–4.PubMedCrossRef

18.

Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: Evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882–91.PubMedCrossRef

19.

Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162(1):100–7.PubMedPubMedCentralCrossRef

20.

Caproni M, Antiga E, Volpi W, Verdelli A, Venegoni L, Quaglino P, et al. The Tre.Th 17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol. 2015;173:275–8.PubMedCrossRef

21.

Quaglino P, Fava P, Caproni M, Antiga E, De Simone C, Papini M, et al. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol. 2016;30:655–8.PubMedCrossRef

22.

Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoimflammatory diseases. Medicine (Baltimore). 2014;93(27):e187.PubMedPubMedCentralCrossRef

23.

24.

Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147:1203–5.PubMedCrossRef

25.

Hideki M, Tetsurou T, Sakae F, Kensei K, Makoto O, Toshinobu K. Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis. Eur J Dermatol. 2013;23(2):256–7.PubMed

26.

Sandhu K, Handa S, Kanwar AJ. Idiopathic pyoderma gangrenosum in a child. Pediatr Dermatol. 2004;21(3):276–7.PubMedCrossRef

27.

Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2016 (Epub 19 Nov 2016).

28.

Patel F, Fitzmaurice S, Duong C, He Y, Fergus J, Raychaudhuri SP, et al. Effectice strategies for the management of pyoderma gangrenosum:a comprehensive review. Acta Derm Venereol. 2015;95:525–31.PubMedCrossRef

29.

Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol. 2015 (Epub 22 Jul 2015).

30.

Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA. 2000;284(12):1546–8.PubMedCrossRef

31.

Zuo KJ, Fung E, Tredget EE, Lin A. A systemic review of post-surgical pyoderma gangrenosum:identification of risk factors and proposed management strategy. J Plast Reconstr Aesthet Surg. 2015;68:295–303.PubMedCrossRef

32.

Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol. 2015;73:615–22.PubMedCrossRef

33.

Ducic I, Odell P, Corsten M. Postoperative Meleney’s ulcer. J Otolaryngol. 1998;27:97–9.PubMed

34.

Pinato DJ, Sharma R. Imatinib induced pyoderma gangrenosum. J Postgrad Med. 2013;59(3):244–5.PubMedCrossRef

35.

Bennett MH, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma Gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79(37–46).

36.

Bhatti H, Khalid N, Rao B. Superficial pyoderma gangrenosum treated with infliximab: a case report. Cutis. 2012;90(6):297–9.PubMed

37.

DeFilippis EM, Feldman SR, Huang B. The genetics of pyoderma gangrenosum an implications for treatment: a systemic review. Br J Dermatol. 2015;172:1487–97.PubMedCrossRef

38.

Binus AM, Qureshi AA, Li V, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patients characteristics, cormorbidities and therapy in 103 patients. Br J Dermatol. 2011;165:1244–50.PubMedCrossRef

39.

Card TR, Langan SM, Chu TP. Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported. Dig Dis Sci. 2016;61(9):2619–26.PubMedCrossRef

40.

Saracino A, Kelly R, Liew D, Chong A. Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up. Australas J Dermatol. 2011;52(3):218–21.PubMedCrossRef

41.

Krüger S, Piroth W, Amo Takyi B, Breuer C, Schwarz ER. Multiple aseptic pulmonary nodules with central necrosis in association with pyoderma gangrenosum. Chest. 2001;119:977–8.PubMedCrossRef

42.

Miserocchi E, Modorati G, Foster CS, Brancato R. Ocular and extracutaneous involvement in pyoderma gangrenosum. Opthalmology. 2002;109:1941–3.CrossRef

43.

Vignon-Pennamen MD. The extracutaneous involvement in the neutrophillic dermatoses. Clin Dermatol. 2000;18:339–47.PubMedCrossRef

44.

Gade M, Studstrup F, Andersen AK, Hilberg O, Fogh C, Bendstrup E. Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respir Med. 2015;109(4):443–50.PubMedCrossRef

45.

Be M, Cha HJ, Park C, Park Y, Jung H, Lee Y, et al. Multiple cavitary nodules with oyoderma gangrenosum in patients with rheumatoid arthritis. Ann Transl Med. 2016;4:39.PubMedPubMedCentralCrossRef

46.

Andrisani G, Guidi L, Papa A, Potenza AE, Cervelli D, Armuzzi A. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery. J Crohn Colitis. 2013;7(5):421–6.CrossRef

47.

Oda F, Tohyama M, Murakami A, Kanno K, Sonobe N, Sayama K. Bromoderma mimicking pyoderma gangrenosum caused by commercial sedatives. J Dermatol. 2016;43(5):564–6.PubMedCrossRef

48.

Goodarzi H, Sivamani RK, Garcia MS, Wehrli LN, Craven H, Ono Y, et al. Effective strategies for the management of pyoderma gangrenosum. Adv Wound Care. 2012;1(5):194–9.CrossRef

49.

Klode J, Stoffels I, Korber A, Weindorf M, Dissemond J. Relationship between the seasonal onset of chronic venous leg ulcers and climatic factors. J Eur Acad Dermatol Venereol. 2011;25(12):1415–9.PubMedCrossRef

50.

Al Ghazal P, Klode J, Dissemond J. Diagnostic criteria for pyoderma gangrenosum: results of a survey among dermatologic wound experts in Germany. J Dtsch Dermatol Ges. 2014;12(12):1129–31.PubMed

51.

Su WP, Davis M, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43:790–800.PubMedCrossRef

52.

Marzano AV, Trevisan V, Lazzari R, Crosti C. Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic’ classification. J Dermatolog Treat. 2011;22(5):254–60.PubMedCrossRef

53.

Tada M, Nakanishi T, Hirata C, Okano T, Sugioka Y, Wakitani S, et al. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Mod Rheumatol. 2010;20(6):598–601.PubMedCrossRef

54.

Wollina U. Pyoderma gangrenosum: a review. Orphanet J Rare Dis. 2007;2:19.PubMedPubMedCentralCrossRef

55.

D’Inca R, Fagiuoli S, Sturniolo GC. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Intern Med. 1998;128(9):783–4.PubMedCrossRef

56.

Weizman A, Huang B, Berel D, Targan SR, Dubinsky M, Fleshner P, et al. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014;20(3):525–33.PubMedPubMedCentralCrossRef

57.

Weizman AV, Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cutan Med Surg. 2014;18(5):361.PubMedPubMedCentralCrossRef

58.

Sinagra E, Orlando A, Renna S, Maida M, Cottone M. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don’t forget the role of cyclosporin. Inflamm Bowel Dis. 2012;18(8):E1594–5.PubMedCrossRef

59.

Langan SM, Powell FC. Vegetative pyoderma gangrenosum: a report of two new cases and a review of the literature. Int J Dermatol. 2005;44(8):623–9.PubMedCrossRef

60.

Handler MZ, Hamilton H, Aires D. Treatment of peristomal pyoderma gangrenosum with topical crushed dapsone. J Drugs Dermatol. 2011;10(9):1059–61.PubMed

61.

Chiba T, Isomura I, Suzuki A, Morita A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol. 2005;32(3):199–203.PubMedCrossRef

62.

Cozzani E, Gasparini G, Parodi A. Pyoderma gangrenosum: a systematic review. G Ital Dermatol Venereol. 2014;149(5):587–600.PubMed

63.

Ambooken B, Khader A, Muhammed K, Rajan U, Snigdha O. Malignant pyoderma gangrenosum eroding the parotid gland successfully treated with dexamethasone pulse therapy. Int J Dermatol. 2014;53(12):1536–8.PubMedCrossRef

64.

Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958.PubMedPubMedCentralCrossRef

65.

Reynoso-von Drateln C, Perla-Navarro AV, Gamez-Nava JI, Gonzalez-Lopez L, Galvan-Villegas F, Ramos-Remus C. Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial. J Rheumatol. 1997;24(4):689–93.PubMed

66.

Wollina U. Pyoderma gangrenosum: a systemic disease? Clin Dermatol. 2015;33(5):527–30.PubMedCrossRef

67.

Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164(13–14):263–73.PubMedCrossRef

68.

Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173(5):1216–23.PubMedCrossRef

69.

Caproni M, Antiga E, Volpi W, Verdelli A, Venegoni L, Quaglino P, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol. 2015;173(1):275–8.PubMedCrossRef

70.

Campanati A, Brisigotti V, Ganzetti G, Molinelli E, Giuliodori K, Consales V, et al. Finally, recurrent pyoderma gangrenosum treated with adalimumab: case report and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(6):1245–7.PubMedCrossRef

71.

Campanati A, Ganzetti G, Giuliodori K, Molinelli E, Offidani A. Biologic therapy in psoriasis: safety profile. Curr Drug Saf. 2016;11(1):4–11.PubMedCrossRef

72.

Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9.PubMedPubMedCentralCrossRef

73.

Adisen E, Oztas M, Gurer MA. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy? Dermatology. 2008;216(2):163–5.PubMedCrossRef

74.

Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5:e8.PubMedPubMedCentral

75.

Chan JL, Graves MS, Cockerell CJ, Pandya AG. Rapid improvement of pyoderma gangrenosum after treatment with infliximab. J Drugs Dermatol. 2010;9(6):702–4.PubMed

76.

Campos-Munoz L, Conde-Taboada A, Aleo E, Toledano E, Lopez-Bran E. Refractory pyoderma gangrenosum treated with infliximab in an infant. Clin Exp Dermatol. 2014;39(3):336–9.PubMedCrossRef

77.

Marzano AV, Tourlaki A, Alessi E, Caputo R. Widespread idiopathic pyoderma gangrenosum evolved from ulcerative to vegetative type: a 10-year history with a recent response to infliximab. Clin Exp Dermatol. 2008;33(2):156–9.PubMedCrossRef

78.

Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: two birds with one stone. World J Gastroenterol. 2009;15(18):2293–5.PubMedPubMedCentralCrossRef

79.

Smith DJ Jr. Use of biobrane in wound management. J Burn Care Rehabil. 1995;16(3 Pt 1):317–20.PubMedCrossRef

80.

Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143(3):306–8.PubMedCrossRef

81.

Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157(6):1274–5.PubMedCrossRef

82.

Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152(5):1059–61.PubMedCrossRef

83.

Saraceno R, Babino G, Chiricozzi A, Zangrilli A, Chimenti S. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol. 2015;72(1):e42–4.PubMedCrossRef

84.

Sagami S, Ueno Y, Tanaka S, Nagai K, Hayashi R, Chayama K. Successful use of adalimumab for treating pyoderma gangrenosum with ulcerative colitis under corticosteroid-tapering conditions. Intern Med. 2015;54(17):2167–72.PubMedCrossRef

85.

Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J. 2010;16(8):15.PubMed

86.

McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol. 2004;3(4):441–4.PubMed

87.

Reguiai Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol. 2007;8(2):67–77.PubMedCrossRef

88.

Kim FS, Pandya AG. The use of etanercept in the treatment of peristomal pyoderma gangrenosum. Clin Exp Dermatol. 2012;37(4):442–3.PubMedCrossRef

89.

Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol. 2007;46(10):1095–9.PubMedCrossRef

90.

Pastor N, Betlloch I, Pascual JC, Blanes M, Banuls J, Silvestre JF. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol. 2006;31(1):152–3.PubMedCrossRef

91.

Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54(3 Suppl 2):S128–34.PubMedCrossRef

92.

Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat. 2005;16(5–6):347–9.CrossRef

93.

Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNFalpha drug—etanercept. J Plast Reconstr Aesthet Surg. 2008;61(4):431–3.PubMedCrossRef

94.

Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol. 2004;10(1):50–2.PubMedCrossRef

95.

Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107(5):794–5.PubMedCrossRef

96.

Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67(5):e237–8.PubMedCrossRef

97.

Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–84.PubMedPubMedCentralCrossRef

98.

Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209–15.PubMedCrossRef

99.

Acquitter M, Plantin P, Kupfer I, Auvinet H, Marhadour T. Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report. Ann Intern Med. 2015;163(1):70–1.PubMedCrossRef

100.

Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161(5):1199–201.PubMedCrossRef

101.

Lin Z, Hegarty JP, Lin T, Ostrov B, Wang Y, Yu W, et al. Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. Inflamm Bowel Dis. 2011;17(6):E41–2.PubMedCrossRef

102.

Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases [in French]. Ann Dermatol Venereol. 2012;139(6–7):459–67.PubMedCrossRef

103.

Patel F, Fitzmaurice S, Duong C, He Y, Fergus J, Raychaudhuri SP, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95(5):525–31.PubMedCrossRef

104.

Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239–41.PubMedCrossRef

105.

Demidowich AP, Freeman AF, Kuhns DB, Aksentijevich I, Gallin JI, Turner ML, et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum. 2012;64(6):2022–7.PubMedCrossRef

106.

Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72(5):678–85.PubMedCrossRef

107.

Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc. 1997;72(7):611–5.PubMedCrossRef

108.

Yeon HB, Lindor NM, Seidman JG, Seidman CE. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet. 2000;66(4):1443–8.PubMedPubMedCentralCrossRef

109.

Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet. 2002;11(8):961–9.PubMedCrossRef

110.

Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH): a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66(3):409–15.PubMedCrossRef

111.

Calderon-Castrat X, Bancalari-Diaz D, Roman-Curto C, Romo-Melgar A, Amoros-Cerdan D, Alcaraz-Mas LA, et al. PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol. 2016;175(1):194–8.PubMedCrossRef

112.

Staub J, Pfannschmidt N, Strohal R, Braun-Falco M, Lohse P, Goerdt S, et al. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol. 2015;29(11):2243–7.PubMedCrossRef

113.

Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142:w13590.PubMed

114.

Leuenberger M, Berner J, Di Lucca J, Fischer L, Kaparos N, Conrad C, et al. PASS Syndrome: an IL-1-driven autoinflammatory disease. Dermatology. 2016;232(2):254–8.PubMedCrossRef

115.

Heymann MC, Rosen-Wolff A. Contribution of the inflammasomes to autoinflammatory diseases and recent mouse models as research tools. Clin Immunol. 2013;147(3):175–84.PubMedCrossRef

116.

Garzorz N, Papanagiotou V, Atenhan A, Andres C, Eyerich S, Eyerich K, et al. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes? J Eur Acad Dermatol Venereol. 2016;30(1):141–3.PubMedCrossRef

117.

Gungor K, Gonen S, Kisakol G, Dikbas O, Kaya A. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006;29(6):575–6.PubMedCrossRef

118.

Boulenger-Vazel A, Kupfer-Bessaguet I, Gouedard C, Leberre R, Leroy JP, Sonnet E, et al. Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies) [in French]. Ann Dermatol Venereol. 2005;132(1):27–31.PubMedCrossRef

119.

Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208(4):339–41.PubMedCrossRef

120.

Darben T, Savige J, Prentice R, Paspaliaris B, Chick J. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas J Dermatol. 1999;40(3):144–6.PubMedCrossRef

121.

Gangaram HB, Tan LP, Gan AT, Suraiya HH, Ganesapillai T. Pyoderma gangrenosum following treatment with isotretinoin. Br J Dermatol. 1997;136(4):636–7.PubMedCrossRef

122.

Hughes BR, Cunliffe WJ. Development of folliculitis and pyoderma gangrenosum in association with abdominal pain in a patient following treatment with isotretinoin. Br J Dermatol. 1990;122(5):683–7.PubMedCrossRef

123.

Levy JM, Richler D, Mahmood MN, Brassard A. Pyoderma gangrenosum associated with alitretinoin therapy. JAAD Case Rep. 2016;2(2):135–7.PubMedPubMedCentralCrossRef

124.

Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22(6):804–5.PubMed

125.

Vestita M, Guida S, Mazzoccoli S, Loconsole F, Foti C. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur J Dermatol. 2015;25(3):272–3.PubMed

126.

Dixit S, Selva-Nayagam P, Hamann I, Fischer G. Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy. J Low Genit Tract Dis. 2015;19(1):e6–9.PubMedCrossRef

127.

Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45(8):1002–3.PubMedCrossRef

128.

Akanay-Diesel S, Hoff NP, Kurle S, Haes J, Erhardt A, Haussinger D, et al. Sunitinib induced pyoderma gangrenosum-like ulcerations. Eur J Med Res. 2011;16(11):491–4.PubMedPubMedCentralCrossRef

129.

Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29(10):e266–7.PubMedCrossRef

130.

Dean SM, Zirwas M. A second case of sunitinib-associated pyoderma gangrenosum. J Clin Aesthet Dermatol. 2010;3(8):34–5.PubMedPubMedCentral

131.

ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159(1):242–3.PubMedCrossRef

132.

Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2006;132(1):115–6.PubMedCrossRef

133.

White LE, Villa MT, Petronic-Rosic V, Jiang J, Medenica MM. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed. 2006;5(2):96–8.PubMedCrossRef

134.

Merkel PA. Drugs associated with vasculitis. Curr Opin Rheumatol. 1998;10(1):45–50.PubMedCrossRef

135.

Glass AT, Bancila E, Milgraum S. Pyoderma gangrenosum in infancy: the youngest reported patient. J Am Acad Dermatol. 1991;25(1 Pt 1):109–10.PubMedCrossRef

136.

Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 1994;130(1):77–81.PubMedCrossRef

137.

Keith PJ, Joyce JC, Wilson BD. Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. Int J Dermatol. 2015;54(9):1075–7.PubMedCrossRef

138.

Tseng E, Alhusayen R, Sade S, Buckstein R, Prica A. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. Br J Haematol. 2015;169(4):461.PubMedCrossRef

139.

Matthews AG, Wylie G. Hydroxycarbamide-induced cutaneous ulceration with a difference. Br J Dermatol. 2014;171(6):1572–4.PubMedCrossRef

140.

Huang W, Nath R, Zayed H, Rubin P, Moore A, Snyder R, et al. Results of an open-label, proof of concept study of gevokizumab in the treatment of the acute, inflammatory phase of pyoderma gangrenosum. Available at: http://www.xoma.com/content/pipeline/documents/X052170_AAD2014_Poster_FINAL.pdf.

141.

Zampeli VA, Lippert U, Nikolakis G, Makrantonaki E, Tzellos TG, Krause U, et al. Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab. J Dermatol Case Rep. 2015;9:62–6.

142.

Akhras V, Sarkany R, Walsh S, Hyde N, Marsden RA. Superficial granulomatous pyoderma treated preoperatively with infliximab. Clin Exp Dermatol. 2009;34:e183-5.

143.

Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. Acta Dermatovenerol Alp Pannonica Adriat. 2006;15:173-7.

144.

Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol. 2005;22:262-5.

145.

Swale VJ, Saha M, Kapur N, Hoffbrand AV, Rustin MH. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol. 2005;30:134-6.

146.

Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813-6.

147.

Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002;34:558-60.

148.

Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatol. 2002;205:278-80.

149.

Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol. 2002;37:863-5.

150.

Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37:1108-10.

151.

Arguelles-Arias F, Castro-Laria L, Lobaton T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58:2949-54.

152.

Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Amer J Gastroenterol. 2003;98:1821-6.

153.

Hinterberger L, Muller CS, Vogt T, Pfohler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther. 2012;2:6.

154.

Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatol Treat. 2011;22:261-5.

155.

Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol. 2004;10:50-2.

156.

Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26:2205–2206.

Titel: Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment
verfasst von: Afsaneh Alavi
Lars E. French
Mark D. Davis
Alain Brassard
Robert S. Kirsner
Publikationsdatum: 01.06.2017
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 3/2017
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-017-0251-7

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Poisoning Through Pediatric Skin: Cases from the Literature

Stasis Dermatitis: Pathophysiology, Evaluation, and Management

Increasing Adherence with Topical Agents for Atopic Dermatitis

Review and Management of Acneiform Eruptions in Patients with Immune Disorders

Tranexamic Acid in the Treatment of Melasma: A Review of the Literature

Melanoma Perception in People of Color: A Targeted Educational Intervention

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie